JP2022502052A5 - - Google Patents

Info

Publication number
JP2022502052A5
JP2022502052A5 JP2021517309A JP2021517309A JP2022502052A5 JP 2022502052 A5 JP2022502052 A5 JP 2022502052A5 JP 2021517309 A JP2021517309 A JP 2021517309A JP 2021517309 A JP2021517309 A JP 2021517309A JP 2022502052 A5 JP2022502052 A5 JP 2022502052A5
Authority
JP
Japan
Prior art keywords
antibody
sequence
hla
seq
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021517309A
Other languages
English (en)
Japanese (ja)
Other versions
JP7588068B2 (ja
JP2022502052A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/053158 external-priority patent/WO2020069133A1/en
Publication of JP2022502052A publication Critical patent/JP2022502052A/ja
Publication of JP2022502052A5 publication Critical patent/JP2022502052A5/ja
Priority to JP2024169203A priority Critical patent/JP2024177227A/ja
Application granted granted Critical
Publication of JP7588068B2 publication Critical patent/JP7588068B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021517309A 2018-09-27 2019-09-26 抗hla-g抗体、抗hla-g抗体を含む組成物、および抗hla-g抗体を使用する方法 Active JP7588068B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024169203A JP2024177227A (ja) 2018-09-27 2024-09-27 抗hla-g抗体、抗hla-g抗体を含む組成物、および抗hla-g抗体を使用する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862737666P 2018-09-27 2018-09-27
US62/737,666 2018-09-27
PCT/US2019/053158 WO2020069133A1 (en) 2018-09-27 2019-09-26 Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024169203A Division JP2024177227A (ja) 2018-09-27 2024-09-27 抗hla-g抗体、抗hla-g抗体を含む組成物、および抗hla-g抗体を使用する方法

Publications (3)

Publication Number Publication Date
JP2022502052A JP2022502052A (ja) 2022-01-11
JP2022502052A5 true JP2022502052A5 (cg-RX-API-DMAC7.html) 2022-10-04
JP7588068B2 JP7588068B2 (ja) 2024-11-21

Family

ID=68296637

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021517309A Active JP7588068B2 (ja) 2018-09-27 2019-09-26 抗hla-g抗体、抗hla-g抗体を含む組成物、および抗hla-g抗体を使用する方法
JP2024169203A Pending JP2024177227A (ja) 2018-09-27 2024-09-27 抗hla-g抗体、抗hla-g抗体を含む組成物、および抗hla-g抗体を使用する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024169203A Pending JP2024177227A (ja) 2018-09-27 2024-09-27 抗hla-g抗体、抗hla-g抗体を含む組成物、および抗hla-g抗体を使用する方法

Country Status (25)

Country Link
US (4) US11208487B2 (cg-RX-API-DMAC7.html)
EP (1) EP3856780A1 (cg-RX-API-DMAC7.html)
JP (2) JP7588068B2 (cg-RX-API-DMAC7.html)
KR (1) KR102867868B1 (cg-RX-API-DMAC7.html)
CN (2) CN115057932B (cg-RX-API-DMAC7.html)
AR (2) AR116526A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019346598B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021005868A2 (cg-RX-API-DMAC7.html)
CL (2) CL2021000761A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021004719A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210197A (cg-RX-API-DMAC7.html)
DO (1) DOP2021000049A (cg-RX-API-DMAC7.html)
EA (1) EA202190609A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP21026339A (cg-RX-API-DMAC7.html)
IL (1) IL281778A (cg-RX-API-DMAC7.html)
MX (1) MX2021003555A (cg-RX-API-DMAC7.html)
MY (1) MY204959A (cg-RX-API-DMAC7.html)
PE (1) PE20211767A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021550690A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202103104RA (cg-RX-API-DMAC7.html)
TW (2) TW202438522A (cg-RX-API-DMAC7.html)
UA (1) UA129052C2 (cg-RX-API-DMAC7.html)
UY (1) UY38391A (cg-RX-API-DMAC7.html)
WO (1) WO2020069133A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA202102034B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY201995A (en) 2018-07-09 2024-03-28 Five Prime Therapeutics Inc Antibodies binding to ilt4
AU2020400030B2 (en) 2019-12-09 2026-05-21 Twist Bioscience Corporation Variant nucleic acid libraries for adenosine receptors
CN115996952A (zh) * 2020-06-11 2023-04-21 提圣纳医疗公司 对hla-g和另一种抗原具有结合特异性的双特异性免疫细胞接合子
WO2022159620A1 (en) * 2021-01-21 2022-07-28 Twist Bioscience Corporation Methods and compositions relating to adenosine receptors
US12012454B2 (en) * 2021-03-24 2024-06-18 China Medical University Hospital Anti-tumor antigen nanobody and nucleic acid encoding sequence thereof, and uses of the same
US11795227B2 (en) * 2021-03-24 2023-10-24 Shine-On Biomedical Co., Ltd. Immunomodulation and anti-tumor-related nanobody and nucleic acid encoding sequence thereof, and uses of the same
GB202111905D0 (en) * 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
CN115925930B (zh) * 2021-11-04 2025-10-31 台州恩泽医疗中心(集团) 一种抗hla-g1、hla-g4及hla-g5异构体分子的单克隆抗体及其用途
US20250297013A1 (en) * 2022-03-25 2025-09-25 Hk Inno.N Corporation Hla-g-specific antibody and use thereof
CN115819583B (zh) * 2022-03-31 2026-03-03 台州恩泽医疗中心(集团) 一种抗hla-g分子的单克隆抗体及其用途
US20250223363A1 (en) * 2022-04-08 2025-07-10 Tizona Therapeutics, Inc. Combination therapy involving anti-hla-g antibodies and anti-egfr antibodies, anti-pd1 or anti-pd-l1 antibodies, and/or anti-cd47
JP2025521577A (ja) * 2022-06-24 2025-07-10 エイチケー イノ.エヌ コーポレーション 免疫チェックポイント制御因子を発現する免疫細胞及びその用途
CN117448412A (zh) * 2022-07-26 2024-01-26 中山大学孙逸仙纪念医院 CD158d分子、其中和抗体,及应用
WO2024108568A1 (zh) * 2022-11-25 2024-05-30 深圳先进技术研究院 抗人类白细胞抗原-g纳米抗体及其制备方法与应用
CN119569891B (zh) * 2023-09-06 2025-09-05 上海恩凯细胞技术有限公司 用于癌症治疗的靶向非经典hla分子的嵌合抗原受体的应用
EP4793288A1 (en) 2023-10-12 2026-08-19 Imbiologics Corp. Antibody specifically binding to hla-g, and use thereof
GB202319122D0 (en) * 2023-12-14 2024-01-31 Kbio Holdings Ltd Antibody
WO2025165879A1 (en) 2024-01-29 2025-08-07 Tizona Therapeutics, Inc. Methods of using anti-hla-g antibodies
TW202612729A (zh) 2024-05-22 2026-04-01 美商提聖納醫療公司 涉及抗hla-g抗體及抗egfr抗體以及抗pd-1抗體之組合療法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
EP0626012B1 (en) 1992-02-11 2003-07-09 Cell Genesys, Inc. Homogenotization of gene-targeting events
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
EP0819171A1 (en) 1995-04-07 1998-01-21 The Regents Of The University Of California Antibodies for the detection of hla-g
US6790638B1 (en) 1998-02-20 2004-09-14 Commissariat A L'energie Atomique Method for selecting tumours expressing HLA-G, sensitive to anticancer treatment and uses
WO2002022784A2 (en) 2000-09-15 2002-03-21 University Of Kansas Medical Center Expression, preparation, uses, and sequence of recombinantly-derived soluble hla-g
JP4860098B2 (ja) 2000-12-18 2012-01-25 ダイアックス、コープ 遺伝的パッケージの焦点を合わせたライブラリー
FR2856599A1 (fr) 2003-06-30 2004-12-31 Commissariat Energie Atomique Utilisation de compositions contenant une forme soluble d'hla-g dans le traitement de pathologies du sang.
WO2005042693A2 (ja) 2003-11-04 2005-05-12 The Animal Engineering Research Institute Hla−eキメラ分子
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
CN1312182C (zh) 2004-10-26 2007-04-25 四川新创生物科技有限公司 抗hla-g的单克隆抗体及分泌它的杂交瘤细胞株、癌症诊断试剂盒及其应用
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
WO2009036379A2 (en) 2007-09-14 2009-03-19 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
US9359424B2 (en) 2009-06-25 2016-06-07 Commissariat A L'energie Atomique Et Aux Energies Alternatives Multimeric polypeptides of HLA-G including alpha1-alpha3 monomers and pharmaceutical uses thereof
CN101967191A (zh) 2009-07-28 2011-02-09 广州天美生物技术有限公司 Hla-g抗体制备方法及其在医学中的应用
MX381912B (es) 2010-07-16 2025-03-13 Adimab Llc Colecciones de anticuerpos.
US20130177574A1 (en) 2012-01-11 2013-07-11 Paul I. Terasaki Foundation Laboratory ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
EP2730588A1 (en) 2012-11-12 2014-05-14 Intelectys Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof
HK1221908A1 (zh) 2013-04-29 2017-06-16 Adimab, Llc 多特异(polyspecificity)试剂,其制备方法和用途
US20190119385A1 (en) 2015-03-27 2019-04-25 University Of Southern California Hla-g as a novel target for car t-cell immunotherapy
CN107849102B (zh) 2015-05-15 2022-05-13 希望之城 嵌合抗原受体组合物
CA3025681A1 (en) * 2016-06-03 2017-12-07 Invectys Anti hla-g specific antibodies
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
BR112021003757A2 (pt) 2018-08-31 2021-05-25 Invectys SA receptores de antígenos quiméricos contra múltiplas isoformas de hla-g

Similar Documents

Publication Publication Date Title
JP7844558B2 (ja) リンパ球における阻害経路の中和
US11202828B2 (en) Therapeutic SIRP-α antibodies
JP2020530289A5 (cg-RX-API-DMAC7.html)
RU2022105827A (ru) Слитые конструкции антител для вовлечения nk-клеток
JP2018533371A5 (cg-RX-API-DMAC7.html)
JP2021521275A5 (cg-RX-API-DMAC7.html)
CN114773475A (zh) Pd-1结合分子和其使用方法
JP2021501162A5 (cg-RX-API-DMAC7.html)
TW201803899A (zh) 三特異性和/或三價結合蛋白
JP2023543896A5 (cg-RX-API-DMAC7.html)
JP2022502052A (ja) 抗hla−g抗体、抗hla−g抗体を含む組成物、および抗hla−g抗体を使用する方法
RU2018126297A (ru) Антитела, нацеленные на cd32b, и способы их применения
EP4508085A1 (en) Antibodies that bind pd-l1, pd-l2 and/or cd28
JP2022514734A5 (cg-RX-API-DMAC7.html)
JP2023547506A5 (cg-RX-API-DMAC7.html)
US20240262913A1 (en) Combination therapy of pd-1-targeted il-2 variant immunoconjugate and anti-tyrp1/anti-cd3 bispecific antibodies
JP2025508066A (ja) 目的としたt細胞活性化のためのcd28二重特異性抗体
JP2023524238A (ja) 治療用SIRPα抗体
JP2023530083A (ja) Hla-g及び別の抗原に対して結合特異性を有する二重特異性免疫細胞エンゲージャー
JP2023549555A5 (cg-RX-API-DMAC7.html)
WO2021092060A1 (en) Methods of treatment
JP2024541476A5 (cg-RX-API-DMAC7.html)
JP2019537449A5 (cg-RX-API-DMAC7.html)
TW202144398A (zh) Cd137結合分子及其用途
AU2024331754A1 (en) Anti-cd20 x anti-cd28 combination therapies